Metastases
Jump to navigation
Jump to search
Metastases are usually an ominous finding. They are not always obvious when in encounter; thus, they should be considered with every diagnosis of a malignant tumour.
Cancers of unknown primary are dealt with in the cancer article. A general approach to undifferentiated tumours is given in the basics article under the heading modified general morphologic DDx of malignancy.
Special types
In-transit metastasis
Definition - the separate tumour nodule must be:[1]
- >2 cm from the primary tumour.
- Arises between the nearest (regional) lymph nodes and the primary tumour.
- The tumour presumably arises from a lymphatic that drains the tissue in which the primary tumour grew.
Notes:
- It is called "in-tranist", as it happens while the tumour is on the way to the regional lymph node.
- In-transit metastases are seen in malignant melanoma, merkel cell carcinoma.
- If a separate tumour nodule <= 2 cm from the primary tumour, it is known as satellitosis.
Specific sites
Internal organs
Lymph node
Main article: Lymph node metastasis
Other
Specific tumours
Melanoma
Main article: Metastatic melanoma
Osteosarcoma
Main article: Osteosarcoma
Sign out
This depends somewhat on the tumour. A synoptic is not done. Margin status should be commented on. A morphologic description is useful if a subsequent resection is done.
Bowel
SMALL BOWEL, RESECTION: - METASTATIC ADENOCARCINOMA, SEE COMMENT. - SURGICAL MARGINS NEGATIVE FOR MALIGNANCY. COMMENT: The tumour involves only the outer aspect of the bowel wall; the bowel mucosa is not involved. The tumour consists of glands with cuboidal tumour cells that have a moderate quantity of pale cytoplasm, and round nuclei. The tumour is moderately differentiated.
Spine
Pending
VERTEBRAL LESION, L1, BIOPSY: - ADENOCARCINOMA -- PENDING IHC.
LESION OF T7 VERTEBRA, CORE BIOPSY: - METASTATIC CARCINOMA, CONSISTENT WITH BREAST PRIMARY, SEE COMMENT. COMMENT: The morphology is compatible with a metastatic breast carcinoma. The tumour cells stain as follows: POSITIVE: CK7, ER, PR, MAMMOGLOBIN. NEGATIVE: CK20, TTF-1, CDX2, HER2, GCDFP. The immunostaining prolife is compatible with a metastatic breast carcinoma. ER, PR and HER2 are interpreted as Class I IHC tests (results used by pathologists), as per the CAP classification.[1] 1. Am J Clin Pathol 133 (3):354-65.
See also
Reference
- ↑ URL: http://www.cancer.gov/dictionary?cdrid=634128. Accessed on: 28 March 2012.